Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 74.02 Billion SEK | 41.01% |
| 2022 | 52.49 Billion SEK | 7.88% |
| 2021 | 48.66 Billion SEK | 0.78% |
| 2020 | 48.28 Billion SEK | 5.75% |
| 2019 | 45.65 Billion SEK | 165.71% |
| 2018 | 17.18 Billion SEK | 57.6% |
| 2017 | 10.9 Billion SEK | 9.31% |
| 2016 | 9.97 Billion SEK | 20.02% |
| 2015 | 8.31 Billion SEK | 30.45% |
| 2014 | 6.37 Billion SEK | -2.28% |
| 2013 | 6.51 Billion SEK | 3.18% |
| 2012 | 6.31 Billion SEK | -5.69% |
| 2011 | 6.69 Billion SEK | -5.23% |
| 2010 | 7.06 Billion SEK | 151.99% |
| 2009 | 2.8 Billion SEK | 8.79% |
| 2008 | 2.57 Billion SEK | 32.38% |
| 2007 | 1.94 Billion SEK | -6.24% |
| 2006 | 2.07 Billion SEK | -23.84% |
| 2005 | 2.72 Billion SEK | 12.73% |
| 2004 | 2.41 Billion SEK | 1.94% |
| 2003 | 2.37 Billion SEK | 19.15% |
| 2002 | 1.99 Billion SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 72.19 Billion SEK | -1.33% |
| 2024 Q2 | 73.16 Billion SEK | -1.81% |
| 2024 Q1 | 74.51 Billion SEK | 0.66% |
| 2023 Q4 | 74.02 Billion SEK | -2.04% |
| 2023 Q1 | 53.91 Billion SEK | 2.7% |
| 2023 Q3 | 75.57 Billion SEK | -0.28% |
| 2023 FY | 74.02 Billion SEK | 41.01% |
| 2023 Q2 | 75.78 Billion SEK | 40.57% |
| 2022 Q1 | 48.8 Billion SEK | 0.3% |
| 2022 Q3 | 50.93 Billion SEK | 5.17% |
| 2022 Q2 | 48.42 Billion SEK | -0.78% |
| 2022 FY | 52.49 Billion SEK | 7.88% |
| 2022 Q4 | 52.49 Billion SEK | 3.07% |
| 2021 Q1 | 48.19 Billion SEK | -0.19% |
| 2021 Q4 | 48.66 Billion SEK | 4.13% |
| 2021 Q3 | 46.73 Billion SEK | 1.16% |
| 2021 Q2 | 46.19 Billion SEK | -4.14% |
| 2021 FY | 48.66 Billion SEK | 0.78% |
| 2020 FY | 48.28 Billion SEK | 5.75% |
| 2020 Q1 | 46.43 Billion SEK | 1.69% |
| 2020 Q2 | 42.64 Billion SEK | -8.16% |
| 2020 Q3 | 44.13 Billion SEK | 3.5% |
| 2020 Q4 | 48.28 Billion SEK | 9.4% |
| 2019 Q3 | 32.79 Billion SEK | 8.7% |
| 2019 FY | 45.65 Billion SEK | 165.71% |
| 2019 Q1 | 29.97 Billion SEK | 74.43% |
| 2019 Q2 | 30.17 Billion SEK | 0.66% |
| 2019 Q4 | 45.65 Billion SEK | 39.23% |
| 2018 FY | 17.18 Billion SEK | 57.6% |
| 2018 Q3 | 16.26 Billion SEK | 34.16% |
| 2018 Q2 | 12.12 Billion SEK | 6.48% |
| 2018 Q1 | 11.38 Billion SEK | 4.43% |
| 2018 Q4 | 17.18 Billion SEK | 5.64% |
| 2017 Q4 | 10.9 Billion SEK | -1.55% |
| 2017 Q3 | 11.07 Billion SEK | 3.68% |
| 2017 Q2 | 10.68 Billion SEK | 3.39% |
| 2017 Q1 | 10.33 Billion SEK | 3.59% |
| 2017 FY | 10.9 Billion SEK | 9.31% |
| 2016 Q1 | 8.53 Billion SEK | 2.73% |
| 2016 Q2 | 9.59 Billion SEK | 12.33% |
| 2016 Q3 | 9.79 Billion SEK | 2.12% |
| 2016 Q4 | 9.97 Billion SEK | 1.84% |
| 2016 FY | 9.97 Billion SEK | 20.02% |
| 2015 Q2 | 6.54 Billion SEK | -0.86% |
| 2015 FY | 8.31 Billion SEK | 30.45% |
| 2015 Q3 | 6.67 Billion SEK | 1.88% |
| 2015 Q4 | 8.31 Billion SEK | 24.56% |
| 2015 Q1 | 6.6 Billion SEK | 3.69% |
| 2014 Q1 | 6.22 Billion SEK | -4.53% |
| 2014 Q3 | 6.37 Billion SEK | 2.0% |
| 2014 Q4 | 6.37 Billion SEK | 0.0% |
| 2014 FY | 6.37 Billion SEK | -2.28% |
| 2014 Q2 | 6.24 Billion SEK | 0.36% |
| 2013 Q1 | 6.56 Billion SEK | 3.95% |
| 2013 FY | 6.51 Billion SEK | 3.18% |
| 2013 Q4 | 6.51 Billion SEK | 0.21% |
| 2013 Q3 | 6.5 Billion SEK | -1.24% |
| 2013 Q2 | 6.58 Billion SEK | 0.3% |
| 2012 Q1 | 6.77 Billion SEK | 1.14% |
| 2012 Q2 | 6.71 Billion SEK | -0.96% |
| 2012 Q3 | 6.55 Billion SEK | -2.29% |
| 2012 Q4 | 6.31 Billion SEK | -3.64% |
| 2012 FY | 6.31 Billion SEK | -5.69% |
| 2011 FY | 6.69 Billion SEK | -5.23% |
| 2011 Q1 | 7.03 Billion SEK | -0.54% |
| 2011 Q2 | 7.09 Billion SEK | 0.84% |
| 2011 Q3 | 6.94 Billion SEK | -2.06% |
| 2011 Q4 | 6.69 Billion SEK | -3.52% |
| 2010 FY | 7.06 Billion SEK | 151.99% |
| 2010 Q4 | 7.06 Billion SEK | -5.17% |
| 2010 Q3 | 7.45 Billion SEK | 0.11% |
| 2010 Q2 | 7.44 Billion SEK | 1.62% |
| 2010 Q1 | 7.32 Billion SEK | 161.21% |
| 2009 Q4 | 2.8 Billion SEK | 0.0% |
| 2009 FY | 2.8 Billion SEK | 8.79% |
| 2008 FY | 2.57 Billion SEK | 32.38% |
| 2007 FY | 1.94 Billion SEK | -6.24% |
| 2006 FY | 2.07 Billion SEK | -23.84% |
| 2005 FY | 2.72 Billion SEK | 12.73% |
| 2004 FY | 2.41 Billion SEK | 1.94% |
| 2003 FY | 2.37 Billion SEK | 19.15% |
| 2002 FY | 1.99 Billion SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -126426.74% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -231227.153% |
| BioGaia AB (publ) | 2.33 Billion SEK | -3072.782% |
| Enzymatica AB (publ) | 125.91 Million SEK | -58693.116% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -215188.643% |
| Gabather AB (publ) | 2.93 Million SEK | -2520397.106% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -101140.427% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | -11562.717% |
| Nanexa AB (publ) | 132.25 Million SEK | -55872.085% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -81363.833% |
| ODI Pharma AB | 12.27 Million SEK | -602971.578% |
| Orexo AB (publ) | 786.6 Million SEK | -9311.009% |
| Probi AB (publ) | 1.55 Billion SEK | -4674.709% |
| Swedencare AB (publ) | 9.52 Billion SEK | -677.423% |
| Toleranzia AB | 160.42 Million SEK | -46043.729% |
| Vivesto AB | 355.87 Million SEK | -20701.347% |